Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KC1036 Food Effect Study
NCT05265338Phase 1Completed
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Mar 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of connitinib in Esophageal Squamous Cell Carcinoma (ESCC) and solid tumor (2 arms), sponsored by Beijing Konruns Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration up to 13 Days, Time to Maximum Plasma Concentration up to 13 Days and 2 more. Started Mar 2022; status: completed.
02
Drugs
connitinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)solid tumor
Beyond the preview
Go deeper on NCT05265338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265338.